UCB to build new manufacturing capacity for Cimzia
The company said that the new manufacturing unit is expected to be operational in 2015 and requires an investment of EUR250m in two steps. UCB Technical Operations &
BeOne Medicines has signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies.